ABMD - ABIOMED, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
265.48
+5.14 (+1.97%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close260.34
Open260.14
Bid262.00 x 800
Ask267.00 x 900
Day's Range260.14 - 266.87
52 Week Range228.00 - 459.75
Volume574,263
Avg. Volume758,900
Market Cap11.979B
Beta (3Y Monthly)1.13
PE Ratio (TTM)47.32
EPS (TTM)5.61
Earnings DateJul 24, 2019 - Jul 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est337.22
Trade prices are not sourced from all markets
  • ABIOMED Gets FDA Confirmation of the Safety of Impella RP
    Zacks14 hours ago

    ABIOMED Gets FDA Confirmation of the Safety of Impella RP

    ABIOMED (ABMD) receives the FDA confirmation of the safety and effectiveness of the company's Impella RP heart pump.

  • FDA clears Abiomed heart pump after concerns over death rate
    American City Business Journals18 hours ago

    FDA clears Abiomed heart pump after concerns over death rate

    Months after federal regulators warned doctors that one of the heart pumps made by Danvers’ Abiomed could be linked to a higher rate of death than previously thought, the company’s device has been cleared by the FDA.

  • Top 5 S&P 500 Stocks for 2018 by Performance
    Investopediayesterday

    Top 5 S&P 500 Stocks for 2018 by Performance

    The Standard & Poor's 500 index—commonly called the S&P 500, or simply the S&P—is the primary gauge of the large-cap U.S. equities market. It is based on the market capitalization figures of the top 500 companies that list their common stock on the NYSE or NASDAQ. Based on available historical data, the S&P has generated an average annual return of around 9.8% from 1928 through 2016.

  • Business Wireyesterday

    FDA Confirms Impella RP is Safe and Effective; Only Right-Sided Device with FDA Approval

    Use of early identification protocol leads to higher survival and native heart recovery, as demonstrated in FDA studies

  • National Cardiogenic Shock Initiative (NCSI) with Impella Best Practices Demonstrates 72% Survival with 98% Native Heart Recovery
    Business Wireyesterday

    National Cardiogenic Shock Initiative (NCSI) with Impella Best Practices Demonstrates 72% Survival with 98% Native Heart Recovery

    Improves upon AMI cardiogenic shock historical survival of 50%

  • ABIOMED (ABMD) to Launch Impella CP With SmartAssist at SCAI
    Zacks3 days ago

    ABIOMED (ABMD) to Launch Impella CP With SmartAssist at SCAI

    ABIOMED's (ABMD) Impella CP receives Japanese PMDA approval in recent times.

  • Top 5 Health Care Stocks of 2018 by Performance
    Investopedia4 days ago

    Top 5 Health Care Stocks of 2018 by Performance

    The healthcare sector performed well in 2018, driven by positive growth in sub-segments such as medical devices, health insurance, hospitals, nursing homes, and pharmaceuticals, which offset losses in biomedical and genetics, home healthcare, medical, and dental supplies. Moving ahead into 2019, as the decade-long expansion faces a period of heightened volatility and risk, the health care sector should benefit from a shift towards more defensive sectors. In a recent sector roundup from Charles Schwab, the firm rated health care at "outperform," citing the group’s strong balance sheets, attractive dividend yields, and improved cost structure.

  • Impella SmartAssist Platform Launches at SCAI, Designed to Further Improve Patient Outcomes
    Business Wire7 days ago

    Impella SmartAssist Platform Launches at SCAI, Designed to Further Improve Patient Outcomes

    Abiomed  announces today that the Impella CP with SmartAssist, which is designed to improve patient outcomes with advanced algorithms and simplified patient management, will be commercially available beginning at the 2019 Society for Cardiovascular Angiography & Interventions Scientific Sessions through a controlled launch process at select sites.

  • ABIOMED's Impella 5.0 and LD Receive Expanded FDA Approvals
    Zacks9 days ago

    ABIOMED's Impella 5.0 and LD Receive Expanded FDA Approvals

    ABIOMED's (ABMD) FDA-approved Impella 2.5 and Impella CP treat certain advanced heart failure patients.

  • FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy
    Business Wire9 days ago

    FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy

    Abiomed (ABMD) announces the U.S. FDA has approved the expansion of the Impella 5.0 and Impella LD PMA labeling for the treatment of cardiogenic shock. The Impella 5.0 and the Impella LD are forward flow heart pumps that deliver up to 5 L/min, stabilizing a patient’s hemodynamics, unloading the left ventricle, and perfusing the end organs, allowing for the potential of native heart recovery or return to heart function baseline. The Impella 5.0 is implanted through the femoral or axillary artery and the Impella LD is implanted directly into the aorta.

  • Is ABIOMED, Inc.'s (NASDAQ:ABMD) High P/E Ratio A Problem For Investors?
    Simply Wall St.10 days ago

    Is ABIOMED, Inc.'s (NASDAQ:ABMD) High P/E Ratio A Problem For Investors?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Motley Fool10 days ago

    Abiomed and Intersect ENT Stumble to Start 2019

    These two med-tech companies failed to impress investors in the first quarter. Is the bull case for owning these stocks still intact?

  • ShockWave Medical's Revenue Soars in Its Public Debut
    Motley Fool12 days ago

    ShockWave Medical's Revenue Soars in Its Public Debut

    The medical device maker's first earnings report as a public company featured explosive revenue growth and upbeat full-year guidance.

  • Motley Fool12 days ago

    2 Winners and 2 Losers in the Med Tech Market This Quarter

    Medical devices can be ultra reliable, lucrative business, but there are plenty of ways for companies to blow it, too.

  • Markit16 days ago

    See what the IHS Markit Score report has to say about Abiomed Inc.

    Abiomed Inc NASDAQ/NGS:ABMDView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for ABMD with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $3.23 billion over the last one-month into ETFs that hold ABMD are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Thomson Reuters StreetEvents16 days ago

    Edited Transcript of ABMD earnings conference call or presentation 2-May-19 12:00pm GMT

    Q4 2019 Abiomed Inc Earnings Call

  • Speedy Medtech: Why This Fast-Growing Stock Should Be On Your Radar
    Investor's Business Daily16 days ago

    Speedy Medtech: Why This Fast-Growing Stock Should Be On Your Radar

    Medical technology stocks hit record highs last year and are rising in 2019. Six of the fastest growing among them have tacked on double-digit earnings growth for several years.

  • ABIOMED Inc. (ABMD) Q4 2019 Earnings Call Transcript
    Motley Fool20 days ago

    ABIOMED Inc. (ABMD) Q4 2019 Earnings Call Transcript

    ABMD earnings call for the period ending March 31, 2019.

  • Associated Press20 days ago

    Qualcomm and Tesla rise while Abiomed and Fluor fall

    The chipmaker's quarterly results beat Wall Street profit forecasts and it expects more than $4.5 billion from a settlement deal with Apple. The oil and gas company reported a plunge in revenue and a surprise loss during the quarter.

  • Medtech CEO Promises To 'Correct The Course' As Shares Dive On Sales Lag
    Investor's Business Daily20 days ago

    Medtech CEO Promises To 'Correct The Course' As Shares Dive On Sales Lag

    Abiomed earnings of $1.60 a share beat expectations, but $207.1 million in sales missed estimates. Sales guidance for fiscal 2020 also disappointed. Abiomed stock plunged early Thursday.

  • Abiomed Comes Up Short as Growth Slows
    Motley Fool20 days ago

    Abiomed Comes Up Short as Growth Slows

    The medical device maker failed to reach its financial targets in the final quarter of its fiscal year.

  • TheStreet.com21 days ago

    Abiomed Shares Fall Following Revenue Miss and Poor Guidance

    were falling Thursday after the company posted disappointing earnings results and guidance before the market opened. Earnings per share for the fourth quarter of the company's fiscal year 2019 came in at $1.04, in line with analysts estimates. Total Impella heart pump revenue, which accounts for the majority of revenue, rose 19% year-over-year to $199.5 million.

  • Reuters21 days ago

    US STOCKS-Wall St inches higher with earnings in spotlight

    U.S. stocks edged higher on Thursday as a handful of positive earnings reports helped investors look past the Federal Reserve's policy decision that dented hopes of interest rate cuts. Among the gainers were financial stocks, which rose 0.5%, helped by MetLife Inc. The insurer's shares rose 3.9% after beating quarterly profit estimates, helped by strong underwriting, volume growth, as well as higher investment income. Qualcomm Inc rose 3.3% after analysts said the chipmaker was well-positioned in the 5G networks space even as it forecast disappointing current-quarter sales.

  • Reuters21 days ago

    US STOCKS-Wall St set for mixed open with earnings in spotlight

    U.S. stocks were set for a flat to slightly higher open on Thursday, as investors assessed the latest batch of earnings, while the Federal Reserve dented hopes of interest rate cut. The benchmark S&P 500 index snapped a three-day streak of closing at record highs on Wednesday after Fed Chairman Jerome Powell stuck with the rate outlook and said the relapse in inflation rates was likely temporary. Traders of U.S. short-term interest rate futures trimmed their bets that the central bank would cut rates before the end of the year.

  • ABIOMED (ABMD) Q4 Earnings Meet Estimates, Sales Rise in Japan
    Zacks21 days ago

    ABIOMED (ABMD) Q4 Earnings Meet Estimates, Sales Rise in Japan

    ABIOMED's (ABMD) Q4 results gain from solid Impella show in Japan.